Anzeige
Erschienen in:
26.06.2017 | Erratum
Erratum to: Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer
Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2017
Einloggen, um Zugang zu erhaltenExcerpt
In the original publication of the article, the labelling for the legend of Fig. 3a was erroneously switched. The corrected Fig. 3 is given in this erratum.
Fig. 3
Analysis of time to progression on standard treatment stratified by genomic biomarkers. a Patients were stratified into a high mutational load or low mutational load group. Time from initiation of treatment to first progression was analyzed using a Cox proportional-hazard model and adjusting for receptor status of the metastatic biopsy, number of lines of therapy and hormonal treatment versus chemotherapy. b Patients were stratified into a TP53 mutation positive or TP53 mutation negative group. Time from initiation of treatment to first progression was analyzed using a Cox proportional-hazard model and adjusting for receptor status of the metastatic biopsy, number of lines of therapy, and hormonal treatment versus chemotherapy
× ![]()
…